APA (7th ed.) Citation

RC, B., MC, T., FC, B., IM, d. S., ACM, C., F, M., . . . R, B. (2025). Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study. Breast cancer research and treatment, 211(1), 131. https://doi.org/10.1007/s10549-025-07628-3

Chicago Style (17th ed.) Citation

RC, Bonadio, et al. "Pathologic Complete Response Rates of Patients with ER-low/HER2-negative Breast Cancer Treated with Neoadjuvant Pembrolizumab Plus Chemotherapy in the Neo-real Study." Breast Cancer Research and Treatment 211, no. 1 (2025): 131. https://doi.org/10.1007/s10549-025-07628-3.

MLA (9th ed.) Citation

RC, Bonadio, et al. "Pathologic Complete Response Rates of Patients with ER-low/HER2-negative Breast Cancer Treated with Neoadjuvant Pembrolizumab Plus Chemotherapy in the Neo-real Study." Breast Cancer Research and Treatment, vol. 211, no. 1, 2025, p. 131, https://doi.org/10.1007/s10549-025-07628-3.